Recurrent chromosome 11q23 abnormalities, including focal gains and losses have been described in mantle cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and in a subset of high-grade B-cell lymphomas lacking *MYC* rearrangements.^[@bib1],\ [@bib2],\ [@bib3]^ We describe a novel fusion of *FOXR1* forkhead box gene, located at 11q23, with a neighboring gene in B-cell lymphoma.

RNAseq and sequencing of cloned PCR products revealed fusion transcripts of 5′ *Ribosomal Protein S25* (*RPS25*) with *FOXR1* in the DLBCL cell line U-2932, both genes located at the amplified chromosomal region 11q23 ([Figure 1a](#fig1){ref-type="fig"}, [Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}). Genomic cloning localized the breakpoint to intron 2/3 of *RPS25* and to the promoter region of *FOXR1* (bp −3532).

Cell line U-2932 comprises two distinct clones traceable to subclones present in the patient\'s tumor.^[@bib4]^ These differences also affected 11q32, *FOXR1* and *RPS25* being tetraploid in subclone R1, and triploid in subclone R2 (3n) ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}). In accordance with the genomic data, the *RPS25*/*FOXR1* fusion was detected in subclone R1 but not in R2 ([Figure 1b](#fig1){ref-type="fig"}). *RPS25*/*FOXR1* was also verified in the patient\'s DNA, which collectively suggested that the fusion had occurred at some later stages of tumor development ([Figure 1b](#fig1){ref-type="fig"}).

Physiological *FOXR1* (formerly *FOXN5*) expression is restricted to the early stages of embryogenesis.^[@bib5],\ [@bib6]^ Ectopic expression as result of 11q23 intrachromosomal deletion-fusion has hitherto been described in neuroblastoma only.^[@bib7]^ In-frame fusions with the 5′ *MLL* or *PAFAH1B2* genes led to overexpression of *FOXR1*.^[@bib7]^ In accordance with the notion that a constitutively expressed 5′ gene (*RPS25*) might be responsible for the ectopic expression of *FOXR1* in B-cell lymphoma also, *FOXR1* levels were 1000 × higher in the fusion-positive than in the fusion-negative U-2932 subclone. Expression array analyses showed that the *RPS25/FOXR1*-positive U-2932 subclone had the highest *FOXR1* expression level of 55 B lymphoma cell lines tested, three log-scales higher than average ([Figure 2a](#fig2){ref-type="fig"}). Quantitative PCR analysis conducted to verify the expression arrays included 17 additional B lymphoma cell lines, revealing that the primary effusion lymphoma cell line CRO-AP3 expressed *FOXR1* at a level similar to the DLBCL cell line U-2932 ([Figure 2b](#fig2){ref-type="fig"}). High-density genomic array analysis demonstrated copy-number transition from 3n to 4n in CRO-AP3, occurring 5′ of *FOXR1* ([Figure 1c](#fig1){ref-type="fig"}, [Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}). Quantitative genomic PCR localized the site of amplification to the first 170 bases of exon 1. 5′-RACE, performed to identify potential 5′-mRNA partners in the two *FOXR1* expressing cell lines, confirmed *RPS25* as fusion partner of *FOXR1* in U-2932. In CRO-AP3, the 5′-RACE PCR product terminated inside the amplified region of *FOXR1* exon 1, upstream of the open reading frame. These results suggested that in CRO-AP3, *FOXR1* overexpression was the result of gene amplification without fusion mRNA formation. Fluorescence *in situ* hybridization using a fosmid clone covering *FOXR1* (G248P85736G6) yielded wild-type signals only restricted to chromosome 11 (not shown), leaving the putative 5′ regulatory gene elusive.

Santo *et al.*^[@bib7]^ reported that *FOXR1* acts as negative regulator of forkhead box factor-mediated transcription and suggested a possible role in tumorigenesis. We found ectopic expression of *FOXR1* in 2/72 (2.8%) B lymphoma cell lines. Both cell lines showed amplification of the *FOXR1* gene. In one cell line, *FOXR1* was fused to a constitutively expressed gene on 11q23, suggesting that the interstitial deletion was responsible for activation of *FOXR1*. Bioinformatic analyses document that the aberrant expression of *FOXR1* is rare, but recurrent in B-cell lymphoma ([Figure 2c](#fig2){ref-type="fig"}).^[@bib8],\ [@bib9],\ [@bib10]^

In conclusion, we show for the first time that *FOXR1* fusions, described as candidate oncogenes in neuroblastoma, also occur in B-cell lymphoma. Cell lines U-2932 and CRO-AP3 are presented as models for the functional analysis of *FOXR1*-mediated cellular events.
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![*FOXR1* aberration in B lymphoma cell lines. (**a**) *RPS25* exon 2 / *FOXR1* exon 2 fusion expressed in U-2932 subclone R1. Two additional transcripts targeting *RPS25* exon 2 with *FOXR1* 5′ sequences were also detected. (**b**) *RPS25/FOXR1* fusion in patient\'s DNA and in one of two subclones of patient-derived cell line. Cell lines OCI-LY3 and HL-60 were used as negative controls. Size of PCR product: 294 bp. (**c**) *FOXR1* was amplified (4n) in CRO-AP3 according to Cytoscan HD Array analysis (Affymetrix, Santa Clara, CA, USA). NTC, nil template control.](bcj201643f1){#fig1}

![*FOXR1* expression in B lymphoma. (**a**) According to expression array analysis, *RPS25* is constitutively expressed in 55 B lymphoma cell lines, *FOXR1* is highest in the *RPS25/FOXR1*-positive U-2932 subclone (red dot). (**b**) Quantitative reverse-transcriptase PCR-verified ectopic expression in U-2932 subclone R1 and in the PEL cell line CRO-AP3. Cell lines NAMALWA (Burkitt\'s lymphoma), CARNAVAL, OCI-LY7 and HT (all DLBCL) do not express *FOXR1*. (**c**) Reanalysis of previously published normalized expression profiling data showing ectopic *FOXR1* expression in primary DLBCL and chronic lymphocytic leukemia (processed data from GEO).^[@bib8],\ [@bib9],\ [@bib10]^ Red dots indicate *FOXR1*-high outliers.](bcj201643f2){#fig2}
